Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study von Schram, Alison M, Subbiah, Vivek, Liao, Chih-Yi (Andy), Moreno, Victor, Desamparados, Roda, Ponz-Sarvise, Mariano, Dotan, Efrat, Cassier, Philippe Alexandre, Moreno, Irene, Varkaris, Andreas, Kim, Richard D, Garralda, Elena, Opdam, Frans, Tai, David, Italiano, Antoine, Oh, Do-Youn, Goyal, Lipika, Fontana, Elisa, Liu, Jia, Boukovala, Myrto, Ghiringelli, Francois, Borad, Mitesh J, Babiker, Hani, Jin, Zhaohui, Millward, Michael, Yachnin, Jeffrey, Kamath, Suneel Deepak, Coward, Jermaine M., Yoo, Changhoon, Kelley, Robin Kate, Sahai, Vaibhav, Bridgewater, John, Springfield, Christoph, Florou, Vaia, El-Khoueiry, Anthony, Eskens, Ferry, Lin, Bruce, Paulson, Scott, Curigliano, Giuseppe, Murphy, Meredith, Deary, Alicia, Ricard, Fabien, Yu Jen, Kai, Ramirez, Florence (Tianhui), Blakesley, Rick E., Schmidt-Kittler, Oleg, Mar, Brenton G., Park, Joon Oh, Hollebecque, Antoine

Volltext

Paraneoplastic Thrombocytosis in Ovarian Cancer von Stone, Rebecca L, Nick, Alpa M, McNeish, Iain A, Balkwill, Frances, Han, Hee Dong, Bottsford-Miller, Justin, Rupaimoole, Rajesha, Armaiz-Pena, Guillermo N, Pecot, Chad V, Coward, Jermaine, Deavers, Michael T, Vasquez, Hernan G, Urbauer, Diana, Landen, Charles N, Hu, Wei, Gershenson, Hannah, Matsuo, Koji, Shahzad, Mian M.K, King, Erin R, Tekedereli, Ibrahim, Ozpolat, Bulent, Ahn, Edward H, Bond, Virginia K, Wang, Rui, Drew, Angela F, Gushiken, Francisca, Collins, Katherine, DeGeest, Koen, Lutgendorf, Susan K, Chiu, Wah, Lopez-Berestein, Gabriel, Afshar-Kharghan, Vahid, Sood, Anil K

Volltext

A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment von KULBE, Hagen, CHAKRAVARTY, Probir, GALLETTA, Laura, SALAKO, Michael A, SMYTH, John F, HAGEMANN, Thorsten, BRENNAN, Donal J, BOWTELL, David D, BALKWILL, Frances R, ANDREW LEINSTER, D, CHARLES, Kellie A, KWONG, Joseph, THOMPSON, Richard G, COWARD, Jermaine I, SCHIOPPA, Tiziana, ROBINSON, Stephen C, GALLAGHER, William M

Volltext

Rethinking ovarian cancer: recommendations for improving outcomes von Bowtell, David D, Vaughan, Sebastian, Coward, Jermaine I, Bast, Robert C, Berchuck, Andy, Berek, Jonathan S, Brenton, James D, Coukos, George, Crum, Christopher C, Drapkin, Ronny, Etemadmoghadam, Dariush, Friedlander, Michael, Gabra, Hani, Kaye, Stan B, Lord, Chris J, Lengyel, Ernst, Levine, Douglas A, McNeish, Iain A, Menon, Usha, Mills, Gordon B, Nephew, Kenneth P, Oza, Amit M, Sood, Anil K, Stronach, Euan A, Walczak, Henning, Balkwill, Frances R

Volltext

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer von COWARD, Jermaine, KULBE, Hagen, SINGH, Naveena, AVRIL, Norbert, CUMMINGS, Jeff, REXHEPAJ, Elton, JIRSTRÖM, Karin, GALLAGHER, William M, BRENNAN, Donal J, MCNEISH, Lain A, BALKWILL, Frances R, CHAKRAVARTY, Probir, LEADER, David, VASSILEVA, Vessela, ANDREW LEINSTER, D, THOMPSON, Richard, SCHIOPPA, Tiziana, NEMETH, Jeffery, VERMEULEN, Jessica

Volltext

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer von Smith, Matthew R, Saad, Fred, Chowdhury, Simon, Oudard, Stéphane, Hadaschik, Boris A, Graff, Julie N, Olmos, David, Mainwaring, Paul N, Lee, Ji Youl, Uemura, Hiroji, Lopez-Gitlitz, Angela, Trudel, Géralyn C, Espina, Byron M, Shu, Youyi, Park, Youn C, Rackoff, Wayne R, Yu, Margaret K, Small, Eric J

Volltext

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial von Iwata, Hiroji, Chia, Stephen K L, Bashford, Anna, Inoue, Kenichi, Armstrong, Anne C, Wong, Alvin, Buyse, Marc, Harvey, Vernon, Smith, John W., Konstantinovic, Zora Neskovic, Rodriguez, Gladys I., Jáñez Martinez, Noelia, Knoop, Ann Soegaard, De Boer, Richard Hendry, Rai, Yoshiaki, Yamamoto, Naohito, Brincat, Stephen, Papish, Steven William, Manalo, Yvonne, Sorensen, Peter Grundtvig, Aogi, Kenjiro, Shimizu, Satoru, Mainwaring, Paul, Chang, Jose, del Barco Berron, Sonia, Dickerson, Laura C., Klein, Leonard M., Ruxer, Robert, Veyret, Corinne, Wagnerova, Maria, Richards, Donald A., Vasileios, Asskikis, Dourthe, Louis Marie, Lu, Yen-Shen, Greenspan, Andrew R., Gonzalez Santiago, Santiago, Perren, Timothy John, Yau, Chung Cheung Thomas, Pikó, Béla, Sato, Nobuaki, Askoy, Sercan, Altundag, Mustafa Kadri, Saip, Pinar, Bajaj, Rajesh, Vestlev, Peter Michael, Dank, Magdolna, Cinieri, Saverio, Suszko-Kazarnowicz, Malgorzata, Yap, Yoon Sim, Chen, Shin-Cheh, Haley, Barbara Bacsik, Inhorn, Roger C., Koynova, Tatyana, Schneeweiss, Andreas, Cubedo Cervera, Ricardo, Urruticoechea Ribate, Ander, Schwartz, Garry H., Mocharnuk, Robert Scott, Alkhouri, Nabiel, Erickson, Nicholette, Traynor, Ann, Volterra, Fabio, Capo, Gerardo, Flaherty, Lawrence E., Baidas, Said, Lybaert, Willem, Holland, David R., Gonzalez Jimenez, Sonia, Vanlemmens, Laurence, Ruggeri, Enzo Maria, Desai, Ajit, Nixon, David Allen, O'Brien, Edward, Lanier, Keith S., Brescia, Frankie Ann, Richard, Vincent, Geldhof, Kurt, Bednarik, Otakar, Schwedler, Kathrin, Fries, Stefan, Klare, Peter, Griesinger, Frank, Trufflandier, Nathalie, Chetiyawardana, Anula D., Papandreou, Christos, Hornyak, Lajos, Simo, Erzsebet, Im, Seock-Ah, Ruit, Jan B., Ciltas, Aydin, Benekli, Mustafa, Conkright, William A., Ottaviano, Yvonne, Delmas, Andrew, Steele, Heather A., Bova, Abby R., Shirinian, Mihran, O'Rourke, Timothy J., Francisco, Michael, Carrillo Flores, Maria Regina

Volltext

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer von ANGLESIO, Michael S, GEORGE, Joshy, CHAKRAVARTY, Probir, GORRINGE, Kylie L, CAMPBELL, Ian G, OKAMOTO, Aikou, BIRRER, Michael J, HUNTSMAN, David G, DE FAZIO, Anna, KALLOGER, Steve E, BALKWILL, Frances, BLAKE GILKS, C, KULBE, Hagen, BOWTELL, David D, FRIEDLANDER, Michael, RISCHIN, Danny, LEMECH, Charlotte, POWER, Jeremy, COWARD, Jermaine, COWIN, Prue A, HOUSE, Colin M

Volltext

Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer von Harrington, Brittney S, He, Yaowu, Davies, Claire M, Wallace, Sarah J, Adams, Mark N, Beaven, Elizabeth A, Roche, Deborah K, Kennedy, Catherine, Chetty, Naven P, Crandon, Alexander J, Flatley, Christopher, Oliveira, Niara B, Shannon, Catherine M, deFazio, Anna, Tinker, Anna V, Gilks, C Blake, Gabrielli, Brian, Brennan, Donal J, Coward, Jermaine I, Armes, Jane E, Perrin, Lewis C, Hooper, John D

Volltext

Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma von Khan, Tashbib, He, Yaowu, Kryza, Thomas, Harrington, Brittney S., Gunter, Jennifer H., Sullivan, Mitchell A., Cuda, Tahleesa, Rogers, Rebecca, Davies, Claire M., Broomfield, Amy, Gough, Madeline, Wu, Andy C., McGann, Thomas, Weroha, S. John, Haluska, Paul, Forbes, Josephine M., Armes, Jane E., Barry, Sinead C., Coward, Jermaine I., Jagasia, Nisha, Chetty, Naven, Snell, Cameron E., Lourie, Rohan, Perrin, Lewis C., Hooper, John D.

Volltext

L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution von Nguyen, Thu H.M., Carreira, Patricia E., Sanchez-Luque, Francisco J., Schauer, Stephanie N., Fagg, Allister C., Richardson, Sandra R., Davies, Claire M., Jesuadian, J. Samuel, Kempen, Marie-Jeanne H.C., Troskie, Robin-Lee, James, Cini, Beaven, Elizabeth A., Wallis, Tristan P., Coward, Jermaine I.G., Chetty, Naven P., Crandon, Alexander J., Venter, Deon J., Armes, Jane E., Perrin, Lewis C., Hooper, John D., Ewing, Adam D., Upton, Kyle R., Faulkner, Geoffrey J.

Volltext

Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer von Harrington, Brittney S, He, Yaowu, Davies, Claire M, Wallace, Sarah J, Adams, Mark N, Beaven, Elizabeth A, Roche, Deborah K, Kennedy, Catherine, Chetty, Naven P, Crandon, Alexander J, Flatley, Christopher, Oliveira, Niara B, Shannon, Catherine M, deFazio, Anna, Tinker, Anna V, Gilks, C Blake, Gabrielli, Brian, Brennan, Donal J, Coward, Jermaine I, Armes, Jane E, Perrin, Lewis C, Hooper, John D

Volltext

Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601) von Smith, Deborah, Robledo, Kristy, Yip, Sonia, Cummins, Michelle, Kok, Peey-Sei, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally E., Shannon, Catherine M., Coward, Jermaine, Beale, Philip James, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine Margaret, Spurdle, Amanda B., Andrews, John, Stockler, Martin R., Mileshkin, Linda R., Antill, Yoland Catherine

Volltext

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA) von Smith, Deborah, Robledo, Kristy P, Yip, Sonia, Cummins, Michelle M, Kok, Peey-Sei, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Spurdle, Amanda B, Andrews, John, Stockler, Martin R, Mileshkin, Linda, Antill, Yoland

Volltext

Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601) von Antill, Yoland Catherine, Kok, Peey Sei, Robledo, Kristy, Barnes, Elizabeth, Friedlander, Michael, Baron-Hay, Sally E., Shannon, Catherine M., Coward, Jermaine, Beale, Philip James, Goss, Geraldine, Meniawy, Tarek, Yip, Sonia, Smith, Deborah, Spurdle, Amanda B., Parry, Michelle, Andrews, John, Kelly, Marzena, Stockler, Martin R., Mileshkin, Linda R.

Volltext

Serum HE4 as a prognostic marker in endometrial cancer — A population based study von Brennan, Donal J, Hackethal, Andreas, Metcalf, Alex M, Coward, Jermaine, Ferguson, Kaltin, Oehler, Martin K, Quinn, Michael A, Janda, Monika, Leung, Yee, Freemantle, Michael, Webb, Penelope M, Spurdle, Amanda B, Obermair, Andreas

Volltext